Stock GEDSF GEDEON RICHTER
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gedeon Richter OTC Markets

Equities

GEDSF

US3684672054

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 09:30:03 2024-04-03 EDT 		5-day change 1st Jan Change
24.85 USD +4.85% Intraday chart for Gedeon Richter -.--% +4.85%
05-31 Gedeon Richter Plc. Approves Dividend Payment in Respect of the 2023 Financial Year CI
05-22 Gedeon Richter plc announces Directorate Changes CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,193,129 1,381,559 1,619,625 1,542,290 1,627,029 1,699,788 - -
Enterprise Value (EV) 1 1,062,663 1,239,491 1,559,769 1,395,557 1,546,536 1,572,497 1,504,888 1,349,892
P/E ratio 24.2 x 13.2 x 11.6 x 9.94 x 10.2 x 7.05 x 6.43 x 5.5 x
Yield 0.98% 3.02% 2.58% 4.7% - 6.01% 6.37% 7.53%
Capitalization / Revenue 2.35 x 2.44 x 2.57 x 1.92 x 2.02 x 2.06 x 1.86 x 1.69 x
EV / Revenue 2.09 x 2.19 x 2.47 x 1.74 x 1.92 x 1.9 x 1.65 x 1.34 x
EV / EBITDA 9.53 x 8.19 x 8.86 x 7.1 x 6.43 x 4.84 x 4.01 x 3.3 x
EV / FCF 26.1 x 18.3 x -460 x 12.3 x 17.9 x 9.86 x 7.93 x 6.21 x
FCF Yield 3.83% 5.47% -0.22% 8.12% 5.6% 10.1% 12.6% 16.1%
Price to Book 1.66 x 1.72 x 1.78 x 1.47 x - 1.34 x 1.24 x 1.08 x
Nbr of stocks (in thousands) 185,991 185,693 185,630 185,818 185,946 182,773 - -
Reference price 2 6,415 7,440 8,725 8,300 8,750 9,300 9,300 9,300
Announcement Date 20-02-07 21-02-26 22-03-02 23-02-28 24-02-29 - - -
1HUF in Million2HUF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 507,794 566,776 630,595 802,755 805,158 826,995 914,452 1,007,751
EBITDA 1 111,534 151,330 176,123 196,480 240,625 324,590 375,410 408,962
EBIT 1 71,863 111,484 135,832 153,555 189,817 263,627 303,741 336,979
Operating Margin 14.15% 19.67% 21.54% 19.13% 23.58% 31.88% 33.22% 33.44%
Earnings before Tax (EBT) 1 51,697 115,164 146,575 165,663 171,540 299,279 319,072 379,742
Net income 1 49,299 104,683 139,626 155,581 158,850 242,144 268,837 323,776
Net margin 9.71% 18.47% 22.14% 19.38% 19.73% 29.28% 29.4% 32.13%
EPS 2 265.0 563.0 751.0 835.0 860.0 1,320 1,447 1,691
Free Cash Flow 1 40,688 67,757 -3,393 113,348 86,554 159,535 189,741 217,468
FCF margin 8.01% 11.95% -0.54% 14.12% 10.75% 19.29% 20.75% 21.58%
FCF Conversion (EBITDA) 36.48% 44.77% - 57.69% 35.97% 49.15% 50.54% 53.18%
FCF Conversion (Net income) 82.53% 64.73% - 72.85% 54.49% 65.88% 70.58% 67.17%
Dividend per Share 2 63.00 225.0 225.0 390.0 - 558.7 592.5 699.9
Announcement Date 20-02-07 21-02-26 22-03-02 23-02-28 24-02-29 - - -
1HUF in Million2HUF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1
Net sales 1 278,692 296,803 157,518 176,274 168,057 192,923 217,807 223,968 209,653 203,783 413,436 188,544 203,178 203,432
EBITDA 1 75,796 80,719 42,943 52,461 - 64,033 77,353 11,597 65,277 52,831 118,108 61,657 59,078 75,175
EBIT 1 55,935 60,800 33,134 41,898 - 51,972 64,840 -740 54,131 40,882 95,013 49,398 44,974 63,607
Operating Margin 20.07% 20.48% 21.04% 23.77% - 26.94% 29.77% -0.33% 25.82% 20.06% 22.98% 26.2% 22.14% 31.27%
Earnings before Tax (EBT) - - - 48,416 - - 87,457 -43,741 - - - - - -
Net income 1 60,531 54,915 - 46,518 37,906 76,532 82,417 -40,422 39,036 28,743 67,936 - - 68,217
Net margin 21.72% 18.5% - 26.39% 22.56% 39.67% 37.84% -18.05% 18.62% 14.1% 16.43% - - 33.53%
EPS - - - 250.0 - 411.0 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 20-08-03 21-08-03 21-11-08 22-03-02 22-05-09 22-08-03 22-11-07 23-02-28 23-05-12 23-08-04 23-08-04 23-11-08 24-02-29 24-05-14
1HUF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 130,466 142,068 59,856 146,733 80,493 127,291 194,900 349,896
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 40,688 67,757 -3,393 113,348 86,554 159,535 189,741 217,468
ROE (net income / shareholders' equity) 9.7% 13.7% 16.2% 15.8% 14.5% 17.7% 18.4% 19.4%
ROA (Net income/ Total Assets) 9.7% 11.6% 13.3% - 11.7% 17% 18% 18%
Assets 1 508,169 903,624 1,046,939 - 1,357,495 1,424,379 1,493,536 1,798,754
Book Value Per Share 2 3,874 4,333 4,910 5,633 - 6,922 7,486 8,647
Cash Flow per Share 2 528.0 723.0 752.0 992.0 670.0 1,556 1,458 1,661
Capex 1 57,552 66,638 143,297 71,579 94,639 93,350 88,152 93,702
Capex / Sales 11.33% 11.76% 22.72% 8.92% 11.75% 11.29% 9.64% 9.3%
Announcement Date 20-02-07 21-02-26 22-03-02 23-02-28 24-02-29 - - -
1HUF in Million2HUF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gedeon Richter

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9,300 HUF
Average target price
11,800 HUF
Spread / Average Target
+26.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.37% 43.54B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+18.30% 21.78B
SANDOZ GROUP AG Stock Sandoz Group AG
+17.66% 15.38B
CIPLA LIMITED Stock Cipla Limited
+25.55% 15.12B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+60.99% 13.36B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-14.84% 6.38B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.17% 5.32B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RICHTER Stock
  4. GEDSF Stock
  5. Financials Gedeon Richter